These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 17903213

  • 1. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
    Koizumi M, Nakaseko C, Ohwada C, Takeuchi M, Ozawa S, Shimizu N, Cho R, Nishimura M, Saito Y.
    Eur J Haematol; 2007 Nov; 79(5):382-91. PubMed ID: 17903213
    [Abstract] [Full Text] [Related]

  • 2. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
    Mitrofan LM, Pelkonen J, Mönkkönen J.
    Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
    [Abstract] [Full Text] [Related]

  • 3. Anticancer effects of zoledronic acid against human osteosarcoma cells.
    Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterlüty H, Scotlandi K, Kotz R, Micksche M, Berger W.
    J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
    [Abstract] [Full Text] [Related]

  • 4. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
    Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ.
    Cancer Res; 1998 Dec 01; 58(23):5294-7. PubMed ID: 9850051
    [Abstract] [Full Text] [Related]

  • 5. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
    Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, Séronie-Vivien S.
    BMC Cancer; 2006 Mar 15; 6():60. PubMed ID: 16539721
    [Abstract] [Full Text] [Related]

  • 6. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
    Yang M, Huang J, Pan HZ, Jin J.
    Int J Mol Med; 2008 Oct 15; 22(4):489-96. PubMed ID: 18813856
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS.
    Eur J Pharmacol; 2007 Sep 10; 570(1-3):27-37. PubMed ID: 17640631
    [Abstract] [Full Text] [Related]

  • 8. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
    Neri P, Yasui H, Hideshima T, Tassone P, Raje N, Catley LP, Ishitsuka K, Blotta S, Kiziltepe T, Ocio EM, Fulciniti M, Kanekal S, Elliott GT, Munshi NC, Anderson KC.
    Br J Haematol; 2006 Jul 10; 134(1):37-44. PubMed ID: 16803565
    [Abstract] [Full Text] [Related]

  • 9. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.
    Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M, Rusconi C, Varettoni M, Lazzarino M.
    Cancer; 2005 Jul 01; 104(1):118-25. PubMed ID: 15895374
    [Abstract] [Full Text] [Related]

  • 10. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
    Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Tada Y, Sekine I, Takiguchi Y, Tatsumi K, Kobayashi H, Shimada H, Hiroshima K, Tagawa M.
    Cell Death Dis; 2014 Nov 13; 5(11):e1517. PubMed ID: 25393473
    [Abstract] [Full Text] [Related]

  • 11. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
    Räikkönen J, Mönkkönen H, Auriola S, Mönkkönen J.
    Biochem Pharmacol; 2010 Mar 01; 79(5):777-83. PubMed ID: 19819230
    [Abstract] [Full Text] [Related]

  • 12. The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
    Ural AU, Yilmaz MI, Avcu F, Pekel A, Zerman M, Nevruz O, Sengul A, Yalcin A.
    Int J Hematol; 2003 Dec 01; 78(5):443-9. PubMed ID: 14704038
    [Abstract] [Full Text] [Related]

  • 13. 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells.
    Agata N, Nogi H, Milhollen M, Kharbanda S, Kufe D.
    Cancer Res; 2004 Dec 01; 64(23):8512-6. PubMed ID: 15574755
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid.
    Morii T, Ohtsuka K, Ohnishi H, Mochizuki K, Satomi K.
    Anticancer Res; 2010 Sep 01; 30(9):3565-71. PubMed ID: 20944138
    [Abstract] [Full Text] [Related]

  • 15. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.
    Tassone P, Galea E, Forciniti S, Tagliaferri P, Venuta S.
    Int J Oncol; 2002 Oct 01; 21(4):867-73. PubMed ID: 12239628
    [Abstract] [Full Text] [Related]

  • 16. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
    Chauhan D, Li G, Auclair D, Hideshima T, Podar K, Mitsiades N, Mitsiades C, Chen LB, Munshi N, Saxena S, Anderson KC.
    Apoptosis; 2004 Mar 01; 9(2):149-55. PubMed ID: 15004512
    [Abstract] [Full Text] [Related]

  • 17. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells.
    Fujita M, Tohi M, Sawada K, Yamamoto Y, Nakamura T, Yagami T, Yamamori M, Okamura N.
    Oncol Rep; 2012 May 01; 27(5):1371-6. PubMed ID: 22322451
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
    Derenne S, Amiot M, Barillé S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R.
    J Bone Miner Res; 1999 Dec 01; 14(12):2048-56. PubMed ID: 10620064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.